Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
Long-term outcomes with frontline nilotinib versus imatin... | ResearchHub
Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis
0
Authors
Hagop Kantarjian
20 more
Hagop Kantarjian
•
Gabriel Étienne
18 more
•
Andreas Hochhaus
Published
January 7, 2021
Paper
Conversation
0
Reviews
0
Bounties
0
Loading PDF viewer…
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
Leukemia
Topics
Biology
Paleontology
Medicine
Internal Medicine
Hematology
Show all topics
DOI
10.1038/s41375-020-01111-2
License
CC-BY
Other Formats
PDF
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
Leukemia
Topics
Biology
Paleontology
Medicine
Internal Medicine
Hematology
Show all topics
DOI
10.1038/s41375-020-01111-2
License
CC-BY
Other Formats
PDF
